CGEM NASDAQ
Cullinan Therapeutics, Inc.
1W: -3.3%
1M: -5.0%
3M: +31.9%
YTD: +72.6%
1Y: +113.6%
3Y: +66.9%
5Y: -36.2%
$17.47
+0.04 (+0.23%)
Weekly Expected Move ±7.0%
$15
$16
$17
$18
$20
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range5.68-19.43
Volume572,133
Avg Volume1,066,572
Beta-0.01
Dividend—
Analyst Ratings
Company Info
CEONadim Ahmed
Employees109
SectorHealthcare
IndustryBiotechnology
IPO Date2021-01-08
Websitecullinantherapeutics.com
One Main Street
Cambridge, MA 02142
US
Cambridge, MA 02142
US
617 410 4650
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Latest News
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
$CGEM stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-07-06 |
| Michaelson Jennifer | S-Sale | 8,000 | $17.82 | 2026-07-06 |
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-07-06 |
| SUMER JACQUELYN L | A-Award | 2,470 | $8.60 | 2026-06-30 |
| Fenton Mary Kay | A-Award | 1,541 | $8.60 | 2026-06-30 |